I'm trying to line up the retatrutide numbers and something isn't fitting. Phase 2 obesity: mean weight reduction was 24.2% at 48 weeks under the efficacy estimand.
Company-reported Phase 3 results from four trials, not peer-reviewed, describe reductions up to 28.7%. NCT05931367 enrolled 445 with knee osteoarthritis, NCT06039826 enrolled 46 postmenopausal participants, and NCT05548231 enrolled 32 Chinese participants. Different populations, durations, maybe different dose arms?
Is the 28.7% mostly longer exposure, higher-dose arms, or a different estimand? Anyone parsed the CTgov records?